- Home
- OMGA vs MURA Comparison
OMGA vs MURA Comparison
Compare OMGA & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMGA
- MURA
- Stock Information
- Founded
- OMGA 2017
- MURA 2013
- Country
- OMGA United States
- MURA Ireland
- Employees
- OMGA N/A
- MURA N/A
- Industry
- OMGA Biotechnology: Pharmaceutical Preparations
- MURA
- Sector
- OMGA Health Care
- MURA
- Exchange
- OMGA Nasdaq
- MURA Nasdaq
- Market Cap
- OMGA 74.5M
- MURA 62.2M
- IPO Year
- OMGA 2021
- MURA N/A
- Fundamental
- Price
- OMGA $1.01
- MURA $3.49
- Analyst Decision
- OMGA Strong Buy
- MURA Strong Buy
- Analyst Count
- OMGA 5
- MURA 4
- Target Price
- OMGA $10.20
- MURA $16.00
- AVG Volume (30 Days)
- OMGA 399.1K
- MURA 50.8K
- Earning Date
- OMGA 11-19-2024
- MURA 11-13-2024
- Dividend Yield
- OMGA N/A
- MURA N/A
- EPS Growth
- OMGA N/A
- MURA N/A
- EPS
- OMGA N/A
- MURA N/A
- Revenue
- OMGA $6,314,000.00
- MURA N/A
- Revenue This Year
- OMGA $127.25
- MURA N/A
- Revenue Next Year
- OMGA N/A
- MURA N/A
- P/E Ratio
- OMGA N/A
- MURA N/A
- Revenue Growth
- OMGA 142.47
- MURA N/A
- 52 Week Low
- OMGA $0.89
- MURA $2.88
- 52 Week High
- OMGA $6.30
- MURA $6.25
- Technical
- Relative Strength Index (RSI)
- OMGA 40.48
- MURA 51.24
- Support Level
- OMGA $1.06
- MURA $3.31
- Resistance Level
- OMGA $1.17
- MURA $3.66
- Average True Range (ATR)
- OMGA 0.11
- MURA 0.17
- MACD
- OMGA -0.01
- MURA -0.01
- Stochastic Oscillator
- OMGA 2.44
- MURA 54.55
About OMGA Omega Therapeutics Inc.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.